Biohaven CEO Vlad Coric Named Ernst & Young Entrepreneur Of The Year 2018 Award Winner in New York Region

NEW HAVEN, Conn., June 13, 2018 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), a clinical-stage biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting neurological diseases, today announced that Ernst & Young (EY) named Biohaven CEO Vlad Coric as the Entrepreneur Of The Year® 2018 Award winner in the Health Care category in the New York region. The awards program recognizes entrepreneurs who are excelling in areas such as innovation, financial performance and personal commitment to their businesses and communities. Dr. Coric was selected as an award winner by a panel of independent judges.

"I am honored to be named an Entrepreneur Of the Year award winner in New York," said Vlad Coric, M.D., CEO. "This distinction reflects the incredible team we have at Biohaven and our commitment to developing treatments for patients with a severe unmet need."

Now in its 32nd year, the Entrepreneur Of the Year program has expanded to recognize business leaders in more than 145 cities and more than 60 countries throughout the world.

Dr. Coric is now eligible for consideration for the Entrepreneur Of The Year National competition. Award winners in several national categories, as well as the Entrepreneur Of The Year National Overall Award winner, will be announced at the Entrepreneur Of The Year National Awards gala in Palm Springs, California, on November 17, 2018. The awards are the culminating event of the Strategic Growth Forum®, the nation's most prestigious gathering of high-growth, market-leading companies.

Sponsors
Founded and produced by EY, the Entrepreneur Of The Year Awards are nationally sponsored in the U.S. by SAP America, the Kauffman Foundation, and Merrill Corporation. In Florida, regional platinum sponsors also included Greenberg Taurig and PNC Bank.

About Biohaven
Biohaven is a clinical-stage biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting neurological diseases, including rare disorders. Biohaven has combined internal development and research with intellectual property licensed from companies and institutions including Bristol-Myers Squibb Company, AstraZeneca AB, Yale University, Catalent, Rutgers, ALS Biopharma LLC and Massachusetts General Hospital. Currently, Biohaven's lead development programs include multiple compounds across its CGRP receptor antagonist and glutamate modulation platforms. The company's common shares are listed on the New York Stock Exchange and traded under the ticker symbol BHVN. More information about Biohaven is available at www.biohavenpharma.com.

For further information, contact Dr. Vlad Coric, the Chief Executive Officer at [email protected]

SOURCE Biohaven Pharmaceutical Holding Company Ltd.